Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | PPARG | P37231 | 12/20 | 0.52 |
| ▸ | PPARA | Q07869 | 12/20 | 0.52 |
| ▸ | STS | P08842 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5004494 | 0.91 | SMN1; SMN2 (0.54) | SMN1; SMN2PPARGPPARASTSL3MBTL1 | |
| SCHEMBL4730249 | 0.87 | SMN1; SMN2 (0.59) | SMN1; SMN2PPARGPPARAL3MBTL1NPC1 | |
| SCHEMBL2720955 | 0.84 | CTRC (0.54) | PPARGPPARASTSHSD17B3 | |
| SCHEMBL2720957 | 0.84 | CTRC (0.54) | PPARGPPARASTSHSD17B3 | |
| SCHEMBL4897738 | 0.84 | SMN1; SMN2 (0.52) | SMN1; SMN2PPARGPPARAL3MBTL1HPGD | |
| SCHEMBL2231218 | 0.83 | SMN1; SMN2 (0.63) | SMN1; SMN2PPARGPPARA | |
| SCHEMBL4731335 | 0.82 | SMN1; SMN2 (0.55) | SMN1; SMN2PPARGPPARA | |
| SCHEMBL2561889 | 0.82 | PPARG (0.68) | SMN1; SMN2PPARGPPARAL3MBTL1HPGD | |
| Methane SCHEMBL27838357 | 0.82 | SMN1; SMN2 (0.61) | SMN1; SMN2PPARGPPARA | |
| SCHEMBL1532659 | 0.81 | SMN1; SMN2 (0.59) | SMN1; SMN2PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319078-A1 | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators | KATAMREDDY SUBBA REDDY | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319078-A1 | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators | GPER1, ESR2, ESRRG | SMN1; SMN2 4741/4885PPARG 63/4885PPARA 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.